Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1982 Jul;76(3):483–489. doi: 10.1111/j.1476-5381.1982.tb09243.x

Protective effects of glucagon during the anaphylactic response in guinea-pig isolated heart

Ivan Andjelkovic, Berislav Zlokovic
PMCID: PMC2071802  PMID: 6179557

Abstract

1 Cardiac anaphylaxis and the effects of glucagon pretreatment were studied in guinea-pig isolated hearts actively sensitized to ovalbumin.

2 Antigen challenge of the sensitized hearts markedly increased creatine phosphokinase (CPK) activity in the coronary venous effluent. Control values of CPK release from the hearts before challenge were 3.56 ± 0.15 mu min-1 mg-1. In the first 10 min following challenge, CPK release remained stable at increased levels which ranged between 4.88 ± 0.20 to 5.39 ± 0.38 mu min-1 mg-1. There was no correlation between immunologically released histamine and CPK release.

3 Pretreatment of the hearts with glucagon (0.15 μmol l-1) exerted a pronounced anti-arrhythmic activity, reducing the conduction arrhythmias and completely preventing automaticity arrhythmias which normally occurred following ovalbumin challenge.

4 Anaphylactic histamine release was reduced significantly in the presence of glucagon. The percentage inhibition of histamine release from glucagon pretreated hearts, during the first 10 min after challenge, ranged between 58% and 94% of that from hearts similarly challenged in the absence of glucagon.

5 Glucagon significantly elevated sinoatrial nodal automaticity, enhanced atrioventricular conduction, improved coronary flow and reduced contractile force during anaphylaxis. It appears that these effects are caused both by modulating anaphylactic histamine release and by influencing the effects of the released histamine.

6 CPK release from the anaphylactic hearts was significantly inhibited in the presence of glucagon. The average percentage inhibition of CPK activity during the first 10 min after challenge ranged between 42% and 98%.

7 The findings from this study provide experimental evidence for protective effects of glucagon pretreatment during cardiac anaphylaxis.

Full text

PDF
483

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anton A. H., Sayre D. F. A modified fluorometric procedure for tissue histamine and its distribution in various animals. J Pharmacol Exp Ther. 1969 Apr;166(2):285–290. [PubMed] [Google Scholar]
  2. Bernauer W. Release of creatine kinase by antigen, histamine, and catecholamines. Naunyn Schmiedebergs Arch Pharmacol. 1976;292(1):67–72. doi: 10.1007/BF00506491. [DOI] [PubMed] [Google Scholar]
  3. Broadley K. J. The role of H1 and H2-receptors in the coronary vascular response to histamine of isolated perfused hearts of guinea-pigs and rabbits. Br J Pharmacol. 1975 Aug;54(4):511–521. doi: 10.1111/j.1476-5381.1975.tb07599.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Burki N. K., Diamond L. Serum creatine phosphokinase activity in asthma. Am Rev Respir Dis. 1977 Aug;116(2):327–331. doi: 10.1164/arrd.1977.116.2.327. [DOI] [PubMed] [Google Scholar]
  5. Capurro N., Levi R. Anaphylaxis in the guinea-pig isolated heart: selective inhibition by burimamide of the positive inotropic and chronotropic effects of released histamine. Br J Pharmacol. 1973 Aug;48(4):620–628. doi: 10.1111/j.1476-5381.1973.tb08249.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Capurro N., Levi R. The heart as a target organ in systemic allergic reactions: comparison of cardiac analphylaxis in vivo and in vitro. Circ Res. 1975 Apr;36(4):520–528. doi: 10.1161/01.res.36.4.520. [DOI] [PubMed] [Google Scholar]
  7. Chemnitz G., Schmidt E., Koller P. U., Busch E. W. Kreatinkinase. Uberarbeitete Standardmethode: Referenzwerte und Klinik. Dtsch Med Wochenschr. 1979 Feb 16;104(7):257–260. doi: 10.1055/s-0028-1103881. [DOI] [PubMed] [Google Scholar]
  8. Dale H. H., Hartley P. Anaphylaxis to the Separated Proteins of Horse-serum. Biochem J. 1916 Oct;10(3):408–433. doi: 10.1042/bj0100408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hurwitz R. A. Effect of glucagon on infants and children with atrioventricular heart block. Br Heart J. 1973 Dec;35(12):1260–1264. doi: 10.1136/hrt.35.12.1260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  11. Levi R., Allan G., Zavecz J. H. Cardiac histamine receptors. Fed Proc. 1976 Jun;35(8):1942–1947. [PubMed] [Google Scholar]
  12. Levi R., Capurro N., Lee C. H. Pharmacological characterization of cardiac histamine receptors: sensitivity to H1-and H2-receptor agonists and antagonists. Eur J Pharmacol. 1975 Feb;30(2):328–335. doi: 10.1016/0014-2999(75)90117-x. [DOI] [PubMed] [Google Scholar]
  13. Levi R. Effects of exogenous and immunologically released histamine on the isolated heart: a quantitative comparison. J Pharmacol Exp Ther. 1972 Aug;182(2):227–238. [PubMed] [Google Scholar]
  14. Levi R. Hypersensitivity reactions of the heart: reduction of anaphylactic crisis by theophylline or glucagon. Bull N Y Acad Med. 1971 Oct;47(10):1229–1229. [PMC free article] [PubMed] [Google Scholar]
  15. Liebig R., Bernauer W., Peskar B. A. Prostaglandin, slow-reacting substance, and histamine release from anaphylactic guinea-pig hearts, and its pharmacological modification. Naunyn Schmiedebergs Arch Pharmacol. 1975;289(1):65–76. doi: 10.1007/BF00498030. [DOI] [PubMed] [Google Scholar]
  16. Lipski J. I., Kaminsky D., Donoso E., Friedberg C. K. Electrophysiological effects of glucagon on the normal canine heart. Am J Physiol. 1972 May;222(5):1107–1112. doi: 10.1152/ajplegacy.1972.222.5.1107. [DOI] [PubMed] [Google Scholar]
  17. MacLeod K. M., Rodgers R. L., McNeill J. H. Characterization of glucagon-induced changes in rate, contractility and cyclic AMP levels in isolated cardiac preparations of the rat and guinea pig. J Pharmacol Exp Ther. 1981 Jun;217(3):798–804. [PubMed] [Google Scholar]
  18. Magro A. M. Creatine phosphokinase in rat mast cells. Immunology. 1980 Mar;39(3):323–330. [PMC free article] [PubMed] [Google Scholar]
  19. Parmley W. W., Sonnenblick E. H. Glucagon: a new agent in cardiac therapy. Am J Cardiol. 1971 Mar;27(3):298–303. doi: 10.1016/0002-9149(71)90307-9. [DOI] [PubMed] [Google Scholar]
  20. Rodgers R. L., MacLeod K. M., McNeill J. H. Responses of rat and guinea pig hearts to glucagon. Lack of evidence for a dissociation between changes in myocardial cyclic 3'5'-adenosine monophosphate and contractility. Circ Res. 1981 Jul;49(1):216–225. doi: 10.1161/01.res.49.1.216. [DOI] [PubMed] [Google Scholar]
  21. Saks V. A., Lipina N. V., Liulina I. V., Chernousova G. B., Fetter R., Smirnov V. I., Chazov E. I. Funktsional'naia kharakteristika kreatinfosfokinaznykh reaktsii, sviazannykh s mitokhondriiami i miofibrillami serdtsa. Biokhimiia. 1976 Aug;41(8):1460–1470. [PubMed] [Google Scholar]
  22. Skov P. S., Geisler A., Klysner R., Norn S. Allergic reactions, cyclic AMP and histamine release. Experientia. 1977 Jul 15;33(7):965–966. doi: 10.1007/BF01951308. [DOI] [PubMed] [Google Scholar]
  23. Tanz R., Opie L. Effect of drug or electrically induced tachyarrhythmias on the release of lactate dehydrogenase (LDH) in isolated perfused guinea-pig hearts. I. Comparison of the effects produced by ouabain, calcium, epinephrine and aconitine. J Pharmacol Exp Ther. 1978 Aug;206(2):320–330. [PubMed] [Google Scholar]
  24. Wilkerson R. D., Partlow D. B., Pruett J. K., Patterson C. W. A possible mechanism of the antiarrhythmic action of glucagon. Eur J Pharmacol. 1977 Jul 1;44(1):57–63. doi: 10.1016/0014-2999(77)90116-9. [DOI] [PubMed] [Google Scholar]
  25. Zavecz J. H., Levi R. Separation of primary and secondary cardiovascular events in systemic anaphylaxis. Circ Res. 1977 Jan;40(1):15–19. doi: 10.1161/01.res.40.1.15. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES